Anti-emetic Drugs
Anti-emetic Drugs - Related Videos
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
0 Views •
Cited by 5 •
2019
A validated computerized battery of neuropsychological and neurophysiological tests is used to study pharmacodynamic effects on the central nervous system of newly developed drugs in early phase development. To demonstrate the test battery, the acute effects of mecamylamine and the reversal of these effects by two agonist drugs are described.
01:30
Drug toxicity: Drug–Drug Interaction
0 Views •
2026
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
0 Views •
Cited by 48 •
2015
Here we describe a technique to cannulate the mesenteric lymph duct in rats which enables quantification of lipid and drug transport via the lymphatic system following intestinal delivery. The technique can be adapted to assess mesenteric lymph concentrations and/or transport of fluid, immune cells, peptides, proteins and lipophilic molecules.
07:32
Novel Apparatus and Method for Drug Reinforcement
0 Views •
Cited by 9 •
2010
Operant drug self-administration and conditioned place preference (CPP) procedures are expansively used in research to model various components of drug reinforcement, consumption, and addiction in humans. In this report, we combined traditional CPP and self-administration methods as a novel approach to studying drug reinforcement and addiction in rats.
FAQs
These medicines act at several points in the emesis network. Blocking serotonin 5-HT3, dopamine D2, histamine H1, muscarinic, or neurokinin-1 receptors can interrupt signaling from the gut or vestibular system to brainstem pathways coordinating vomiting. The relevant receptor target depends on the provoking condition, so pharmacological selection is mechanism-driven rather than symptom-only.
A drug’s effectiveness depends partly on whether the emetic signal begins in the gastrointestinal tract, vestibular system, or another pathway involved in the condition. Motion sickness, surgery, gastrointestinal illness, pregnancy, and anticancer treatment can therefore require different receptor-focused choices. Matching the agent to the trigger improves the likelihood of controlling symptoms while limiting unnecessary pharmacological exposure.
Receptor selectivity helps explain why different agents produce different unwanted effects. Activity involving histamine H1 or muscarinic pathways may be associated with drowsiness or dry mouth, whereas effects linked with dopamine D2 pathways can include movement disorders. Pharmacology therefore considers both the pathway driving emesis and the adverse-effect profile when choosing treatment.
These receptor classes represent distinct signaling opportunities within the emesis pathway. Serotonin 5-HT3 and dopamine D2 targets, along with neurokinin-1 targets, allow treatment to interrupt vomiting-related communication through different mechanisms. Their inclusion in drug selection reflects the need to address the biology of a particular trigger rather than assuming that every cause responds identically.
Selection begins by identifying the context causing nausea or vomiting, such as motion, surgery, gastrointestinal illness, pregnancy, or anticancer treatment. Pharmacologists then consider which receptor pathways are relevant and weigh expected adverse effects, including drowsiness, dry mouth, or movement disorders. An appropriate agent, or in some situations a combination, is chosen to support symptom control and recovery.
They are particularly relevant when nausea or vomiting threatens hydration, medication adherence, or recovery. Important settings include chemotherapy-induced nausea, postoperative vomiting, motion sickness, pregnancy, and gastrointestinal illness. Studying these uses shows how pharmacological treatment is adapted to the source of emetic signaling and to the practical consequences of uncontrolled symptoms.
Controlling nausea and vomiting can help maintain hydration, support adherence to other medicines, and facilitate recovery after illness or surgery. In anticancer care, symptom management is relevant to chemotherapy-induced nausea, while motion-related symptoms require attention to vestibular signaling. These outcomes illustrate why anti-emetic therapy has functional importance beyond immediate relief.